These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 2559541)
1. Characterization of human T-cell lines harboring defective human immunodeficiency virus type 1. Hamamoto Y; Takamatsu K; Kobayashi S; Yamaguchi K; Yamamoto N; Kobayashi N Virus Genes; 1989 Nov; 3(2):141-52. PubMed ID: 2559541 [TBL] [Abstract][Full Text] [Related]
2. Variation of secretory antibodies in parotid saliva to human immunodeficiency virus type 1 with HIV-1 disease stage. Sun D; Archibald DW; Furth PA AIDS Res Hum Retroviruses; 1990 Jul; 6(7):933-41. PubMed ID: 2117957 [TBL] [Abstract][Full Text] [Related]
3. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393 [TBL] [Abstract][Full Text] [Related]
4. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Akerblom L; Nara P; Dunlop N; Putney S; Morein B Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967 [TBL] [Abstract][Full Text] [Related]
5. In vitro modification of human immunodeficiency virus type 1 (HIV-1) infectivity by the U937 cells. el-Farrash MA; Masuda T; Kuroda MJ; Harada S Microbiol Immunol; 1993; 37(5):349-57. PubMed ID: 8355620 [TBL] [Abstract][Full Text] [Related]
6. Cells surviving infection by human immunodeficiency virus type 1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. Kishi M; Nishino Y; Sumiya M; Ohki K; Kimura T; Goto T; Nakai M; Kakinuma M; Ikuta K J Gen Virol; 1992 Jan; 73 ( Pt 1)():77-87. PubMed ID: 1730943 [TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1. Robert V; Resnicoff M; Chermann JC; Devaux C Mol Cell Biochem; 1991 Apr; 102(2):115-23. PubMed ID: 1715507 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins. Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136 [TBL] [Abstract][Full Text] [Related]
9. Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro. Montefiori DC; Zhou JY Antiviral Res; 1991 Jan; 15(1):11-25. PubMed ID: 1709802 [TBL] [Abstract][Full Text] [Related]
10. Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. Bouyac M; Rey F; Nascimbeni M; Courcoul M; Sire J; Blanc D; Clavel F; Vigne R; Spire B J Virol; 1997 Mar; 71(3):2473-7. PubMed ID: 9032385 [TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of human immunodeficiency virus type 1 antibody reactivity by western immunoblots: evaluation of relative antibody levels in seropositive individuals and mothers. Geffin RB; Lai SH; Hutto C; Scott GB; Scott WA; Master M; Parks WP J Infect Dis; 1992 Jan; 165(1):111-8. PubMed ID: 1727880 [TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients. Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of T cell antigen receptor-dependent phosphorylation of CD4 in human immunodeficiency virus type 1 infected cells. Gaulton GN; Brass LF; Kozbor D; Pletcher CH; Hoxie JA J Biol Chem; 1992 Feb; 267(6):4102-9. PubMed ID: 1310988 [TBL] [Abstract][Full Text] [Related]
14. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603 [TBL] [Abstract][Full Text] [Related]
15. Permissivity of primary cultures of human Kupffer cells for HIV-1. Schmitt MP; Gendrault JL; Schweitzer C; Steffan AM; Beyer C; Royer C; Jaeck D; Pasquali JL; Kirn A; Aubertin AM AIDS Res Hum Retroviruses; 1990 Aug; 6(8):987-91. PubMed ID: 2121193 [TBL] [Abstract][Full Text] [Related]
16. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605 [TBL] [Abstract][Full Text] [Related]
17. Anoxia induces human immunodeficiency virus expression in infected T cell lines. Polonis VR; Anderson GR; Vahey MT; Morrow PJ; Stoler D; Redfield RR J Biol Chem; 1991 Jun; 266(18):11421-4. PubMed ID: 1904863 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens. Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590 [TBL] [Abstract][Full Text] [Related]
19. Computer predictions of antigenic domains in human immunodeficiency virus-1 envelope glycoprotein: comparison with reported experimental data. Becker Y Virus Genes; 1990 Apr; 3(4):323-41. PubMed ID: 1693457 [TBL] [Abstract][Full Text] [Related]
20. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope. Achour A; Picard O; Mbika JP; Willer A; Snart R; Bizzini B; Carelli C; Burny A; Zagury D Vaccine; 1993; 11(7):609-701. PubMed ID: 7688170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]